SUPPLEMENTAL MATERIAL

Predicted Atherosclerotic Cardiovascular Disease Risk and Masked Hypertension Among African Americans in the Jackson Heart Study

Short title: Cardiovascular disease risk and masked hypertension

D. Edmund Anstey, MD¹, John N. Booth, III², MS, Marwah Abdalla, MD, MPH¹, Tanya M. Spruill, PhD³, Yuan-I Min, PhD⁴, Paul Muntner², PhD, Daichi Shimbo, MD¹

¹Columbia University Medical Center, New York, New York

²University of Alabama at Birmingham, Birmingham, Alabama

³New York University School of Medicine, New York, New York

⁴School of Medicine, University of Mississippi Medical Center, Jackson, Mississippi

SUPPLEMENTAL TABLES

Supplemental Table 1. Clinic and ambulatory blood pressure levels among Jackson Heart Study

participants by category of 10-year predicted atherosclerotic cardiovascular risk.

| | 1 | y | | | |
|--------------------|------------------|------------------|------------------|------------------|---------|
| | <5% | ≥5% to <7.5% | ≥7.5% to <10% | ≥10% | p-trend |
| | (n=212) | (n=93) | (n=74) | (n=265) | |
| SBP, mmHg | | | | | |
| Clinic SBP | 117.3 ± 10.2 | 121.2 ± 9.5 | 122.5 ± 10.6 | 125.9 ± 9.3 | < 0.001 |
| Daytime SBP | 121.9 ± 9.7 | 125.9 ± 10.9 | 126.7 ± 10.1 | 131.2 ± 12.4 | < 0.001 |
| Nighttime SBP | 111.7 ± 11.4 | 116.3 ± 13.2 | 118.0 ± 11.0 | 123.0 ± 15.1 | < 0.001 |
| 24-hour SBP | 117.8 ± 9.7 | 122.3 ± 10.8 | 123.7 ± 9.9 | 128.0 ± 12.5 | < 0.001 |
| DBP, mmHg | | | | | |
| Clinic DBP | 74.2 ± 7.7 | 73.5 ± 7.5 | 72.5 ± 8.0 | 72.3 ± 6.9 | 0.003 |
| Daytime DBP | 77.7 ± 8.4 | 77.2 ± 7.7 | 76.6 ± 8.3 | 77.2 ± 9.5 | 0.473 |
| Nighttime DBP | 66.4 ± 8.7 | 66.2 ± 9.1 | 68.2 ± 8.5 | 68.3 ± 10.1 | 0.015 |
| 24-hour DBP | 73.2 ± 8.0 | 72.7 ± 7.5 | 73.5 ± 7.9 | 73.5 ± 9.0 | 0.553 |
| Prehypertension, % | 47.2% | 61.3% | 64.9% | 77.4% | < 0.001 |

The numbers in the table are mean \pm standard deviation or percentages.

ASCVD: Atherosclerotic cardiovascular disease

SBP: systolic blood pressure DBP: diastolic blood pressure

Supplemental Table 2. Characteristics and clinic and ambulatory blood pressure among Jackson Heart Study participants by category of 10-year predicted atherosclerotic cardiovascular risk stratified by those not taking antihypertensive medication (upper panel) and those taking antihypertensive medication (lower panel).

| medication (lower panel). | T | | | |
|-------------------------------------|-------------------|--------------------|------------------|---------------|
| | 10-year pre | edicted ASCVD ri | sk category | |
| | <5% | \geq 5% to <7.5% | ≥7.5% | p-trend |
| Participa | nts not taking a | ntihypertensive me | edication | |
| | (n=159) | (n=45) | (n=101) | |
| Age, years | 49.3 ± 6.1 | 57.0 ± 6.1 | 66.0 ± 6.4 | < 0.001 |
| Male, % | 18.2% | 62.2% | 51.5% | < 0.001 |
| Less than high school | 4.4% | 17.8% | 21.8% | < 0.001 |
| education, % | 4.470 | 17.070 | 21.070 | \0.001 |
| Current smoking, % | 6.9% | 4.4% | 13.9% | 0.074 |
| Diabetes, % | 1.9% | 4.4% | 26.7% | < 0.001 |
| eGFR < 60 ml/min/m ² , % | 0.0% | 2.2% | 8.9% | 0.014 |
| Body mass index, kg/m ² | 30.7 ± 7.6 | 29.8 ± 6.0 | 29.8 ± 5.0 | 0.254 |
| Total cholesterol, mg/dL | 198.2 ± 36.5 | 206.5 ± 34.4 | 216.8 ± 42.0 | < 0.001 |
| LDL cholesterol, mg/dL | 124.3 ± 35.9 | 136.7 ± 33.2 | 139.8 ± 36.6 | < 0.001 |
| HDL cholesterol, mg/dL | 55.5 ± 13.2 | 49.4 ± 12.9 | 55.6 ± 16.2 | 0.832 |
| SBP, mmHg | | | | |
| Clinic SBP | 116.9 ± 10.5 | 120.1 ± 9.6 | 126.1 ± 8.4 | < 0.001 |
| Daytime SBP | 121.5 ± 9.4 | 127.3 ± 10.2 | 130.4 ± 11.1 | < 0.001 |
| Nighttime SBP | 111.4 ± 10.7 | 117.0 ± 12.9 | 120.8 ± 13.5 | < 0.001 |
| 24-hour SBP | 117.4 ± 9.4 | 123.5 ± 10.6 | 126.8 ± 11.4 | < 0.001 |
| DBP, mmHg | | | | |
| Clinic DBP | 74.0 ± 7.6 | 73.4 ± 8.2 | 72.2 ± 6.0 | 0.060 |
| Daytime DBP | 77.3 ± 8.4 | 79.1 ± 6.9 | 77.4 ± 8.7 | 0.824 |
| Nighttime DBP | 66.1 ± 8.2 | 68.6 ± 9.1 | 68.6 ± 8.7 | 0.016 |
| 24-hour DBP | 72.8 ± 7.9 | 74.8 ± 7.1 | 73.9 ± 7.9 | 0.226 |
| Prehypertension, % | 47.2% | 57.8% | 80.2% | < 0.001 |
| Partici | pants taking anti | hypertensive med | ication | |
| | (n=53) | (n=48) | (n=238) | |
| Age, years | 50.6 ± 5.9 | 58.5 ± 7.2 | 65.0 ± 7.2 | < 0.001 |
| Male, % | 1.9% | 6.3% | 33.6% | < 0.001 |
| Less than high school | 11.3% | 20.8% | 19.9% | 0.209 |
| education, % | 11.5/0 | 20.670 | 19.9/0 | 0.209 |
| Current smoking, % | 1.9% | 10.4% | 8.0% | 0.234 |
| Diabetes, % | 1.9% | 8.3% | 37.8% | < 0.001 |
| $eGFR < 60 \text{ ml/min/m}^2, \%$ | 0.0% | 8.3% | 16.0% | 0.004 |
| Body mass index, kg/m ² | 32.6 ± 7.4 | 33.4 ± 5.7 | 31.1 ± 5.7 | 0.034 |
| Total cholesterol, mg/dL | 192.8 ± 32.2 | 193.7 ± 37.3 | 203.2 ± 40.9 | 0.041 |
| LDL cholesterol, mg/dL | 115.0 ± 31.5 | 115.4 ± 36.6 | 126.1 ± 35.2 | 0.015 |
| HDL cholesterol, mg/dL | 60.3 ± 19.5 | 56.1 ± 15.1 | 53.8 ± 13.6 | 0.004 |

| SBP, mmHg | | | | |
|--------------------|------------------|------------------|------------------|---------|
| Clinic SBP | 118.4 ± 9.3 | 122.3 ± 9.4 | 124.8 ± 10.2 | < 0.001 |
| Daytime SBP | 123.0 ± 10.6 | 124.5 ± 11.4 | 130.1 ± 12.5 | < 0.001 |
| Nighttime SBP | 112.7 ± 13.3 | 115.7 ± 13.6 | 122.4 ± 14.9 | < 0.001 |
| 24-hour SBP | 119.0 ± 10.6 | 121.2 ± 10.9 | 127.2 ± 12.4 | < 0.001 |
| DBP, mmHg | | | | |
| Clinic DBP | 74.9 ± 8.0 | 73.7 ± 6.9 | 72.3 ± 7.6 | 0.018 |
| Daytime DBP | 79.1 ± 8.5 | 75.4 ± 8.0 | 76.9 ± 9.4 | 0.262 |
| Nighttime DBP | 67.3 ± 10.1 | 64.0 ± 8.6 | 68.1 ± 10.2 | 0.216 |
| 24-hour DBP | 74.4 ± 8.2 | 70.7 ± 7.3 | 73.4 ± 9.1 | 0.911 |
| Prehypertension, % | 47.2% | 64.6% | 72.3% | < 0.001 |

The numbers in the table are mean \pm standard deviation or percentages.

ASCVD: Atherosclerotic cardiovascular disease

eGFR: estimated glomerular filtration rate

HDL: high-density lipoprotein LDL: low-density lipoprotein SBP: systolic blood pressure DBP: diastolic blood pressure

Supplemental Table 3. Prevalence and prevalence ratios for masked hypertension by category of 10-year predicted atherosclerotic cardiovascular disease risk among participants not taking antihypertensive medication (upper panel) and taking antihypertensive medication (bottom panel).

| | 10-year predicted ASCVD risk category | | | | | | |
|---|---------------------------------------|--------------------|------------------------|---------|--|--|--|
| | <5% | \geq 5% to <7.5% | ≥7.5% | p-trend | | | |
| Participants not taking antihypertensive medication | (n=159) | (n=45) | (n=101) | | | | |
| | | Pro | evalence | | | | |
| Any masked hypertension | 35.2% | 62.2% | 63.4% | < 0.001 | | | |
| Masked daytime hypertension | 20.1% | 31.1% | 37.6% | 0.002 | | | |
| Masked nighttime hypertension | 33.3% | 53.3% | 61.4% | < 0.001 | | | |
| Masked 24-hour hypertension | 22.0% | 40.0% | 46.5% | < 0.001 | | | |
| | | Unadjusted prev | valence ratio (95% CI) | | | | |
| Any masked hypertension | 1 (ref) | 1.60 (1.13 - 2.27) | 1.84 (1.41 - 2.41) | < 0.001 | | | |
| Masked daytime hypertension | 1 (ref) | 1.55 (0.91 - 2.64) | 1.87 (1.25 - 2.79) | 0.002 | | | |
| Masked nighttime hypertension | 1 (ref) | 1.77 (1.30 - 2.41) | 1.80 (1.39 - 2.33) | < 0.001 | | | |
| Masked 24-hour hypertension | 1 (ref) | 1.82 (1.14 - 2.88) | 2.11 (1.48 - 3.03) | < 0.001 | | | |
| | Adjusted prevalence ratio (95% CI)* | | | | | | |
| Any masked hypertension | 1 (ref) | 1.62 (1.07 - 2.46) | 1.94 (1.22 - 3.10) | 0.006 | | | |
| Masked daytime hypertension | 1 (ref) | 1.49 (0.79 - 2.80) | 1.88 (0.97 - 3.67) | 0.064 | | | |
| Masked nighttime hypertension | 1 (ref) | 1.85 (1.27 - 2.71) | 2.09 (1.35 - 3.23) | 0.001 | | | |
| Masked 24-hour hypertension | 1 (ref) | 2.12 (1.22 - 3.66) | 2.65 (1.48 - 4.76) | 0.001 | | | |
| Participants taking antihypertensive medication | (n=53) | (n=48) | (n=238) | | | | |
| | Prevalence | | | | | | |
| Any masked hypertension | 47.2% | 39.6% | 65.5% | 0.001 | | | |
| Masked daytime hypertension | 22.6% | 22.9% | 40.3% | 0.004 | | | |
| Masked nighttime hypertension | 41.5% | 31.3% | 59.2% | 0.002 | | | |
| Masked 24-hour hypertension | 20.8% | 16.7% | 44.1% | < 0.001 | | | |
| ~ 1 | Unadjusted prevalence ratio (95% CI) | | | | | | |
| Any masked hypertension | 1 (ref) | 0.75 (0.44 - 1.28) | 1.43 (1.02 - 2.00) | 0.006 | | | |

| Masked daytime hypertension | 1 (ref) | 1.01 (0.49 - 2.08) | 1.78 (1.06 - 3.00) | 0.009 | | | |
|-------------------------------|-------------------------------------|--------------------|--------------------|--------|--|--|--|
| Masked nighttime hypertension | 1 (ref) | 0.84 (0.53 - 1.32) | 1.39 (1.03 - 1.87) | 0.005 | | | |
| Masked 24-hour hypertension | 1 (ref) | 0.80 (0.35 - 1.83) | 2.13 (1.23 - 3.67) | <0.001 | | | |
| | Adjusted prevalence ratio (95% CI)* | | | | | | |
| Any masked hypertension | 1 (ref) | 0.72 (0.43 - 1.22) | 1.21 (0.81 - 1.81) | 0.154 | | | |
| Masked daytime hypertension | 1 (ref) | 1.30 (0.63 - 2.67) | 2.14 (1.17 - 3.94) | 0.008 | | | |
| Masked nighttime hypertension | 1 (ref) | 0.89 (0.57 - 1.40) | 1.38 (0.96 - 1.98) | 0.031 | | | |
| Masked 24-hour hypertension | 1 (ref) | 0.84 (0.37 - 1.90) | 1.86 (1.02 - 3.39) | 0.015 | | | |

ASCVD: Atherosclerotic cardiovascular disease

CI: Confidence interval

^{*}Adjusted for age, sex, body mass index, less than high school education, and estimated glomerular filtration rate <60 ml/min/m²

Supplemental Table 4. Distribution of 10-year predicted atherosclerotic cardiovascular disease risk categories among Jackson Heart Study participants with and without masked hypertension.

| | Type of masked hypertension | | | | | | | | |
|---------------------|-----------------------------|-------|---------|-------|-----------|-------|---------|-------|--|
| | Any | | Daytime | | Nighttime | | 24-hour | | |
| ASCVD risk category | No | Yes | No | Yes | No | Yes | No | Yes | |
| | n=441 | n=203 | n=327 | n=317 | n=420 | n=224 | n=296 | n=348 | |
| <5% | 44.3% | 23.3% | 38.1% | 21.7% | 41.9% | 23.7% | 39.5% | 20.5% | |
| ≥5% to <7.5% | 15.5% | 13.5% | 15.4% | 12.3% | 16.5% | 12.3% | 16.0% | 11.6% | |
| ≥7.5% to <10% | 10.5% | 12.4% | 11.6% | 11.3% | 10.7% | 12.3% | 11.4% | 11.6% | |
| ≥10% | 29.7% | 50.9% | 34.9% | 54.7% | 30.9% | 51.7% | 33.1% | 56.3% | |

ASCVD: Atherosclerotic cardiovascular disease

Supplemental Table 5. Prevalence of 10-year predicted atherosclerotic cardiovascular disease risk categories among participants with and without masked hypertension stratified by those not taking antihypertensive medication (upper panel) and those taking antihypertensive

medication (lower panel).

| | Type of masked hypertension | | | | | | | |
|---------------------|-----------------------------|-------|---------------|--------------|--------------|--------------|---------|-------|
| | Any | | Daytime | | Nighttime | | 24-hour | |
| | No | Yes | No | Yes | No | Yes | No | Yes |
| ASCVD risk category | | Par | ticipants no | t taking ant | ihypertensiv | e medication | ons | |
| | n=221 | n=84 | n=166 | n=139 | n=205 | n=100 | n=157 | n=148 |
| <5% | 57.5% | 38.1% | 63.9% | 38.1% | 60.5% | 35.0% | 65.6% | 37.8% |
| ≥5% to <7.5% | 14.0% | 16.7% | 12.7% | 17.3% | 13.2% | 18.0% | 10.8% | 18.9% |
| ≥7.5% | 28.5% | 45.2% | 23.5% | 44.6% | 26.3% | 47.0% | 23.6% | 43.2% |
| ASCVD risk category | | P | articipants t | aking antih | ypertensive | medication | IS | |
| | n=220 | n=119 | n=161 | n=178 | n=215 | n=124 | n=139 | n=200 |
| <5% | 18.6% | 10.1% | 19.3% | 12.4% | 19.5% | 8.9% | 20.1% | 12.5% |
| ≥5% to <7.5% | 16.8% | 9.2% | 20.5% | 8.4% | 18.6% | 6.5% | 20.9% | 9.5% |
| ≥7.5% | 64.5% | 80.7% | 60.2% | 79.2% | 61.9% | 84.7% | 59.0% | 78.0% |

ASCVD: Atherosclerotic cardiovascular disease

Supplemental Table 6. Prevalence and prevalence ratios for masked hypertension by category of atherosclerotic cardiovascular disease risk among Jackson Heart Study participants with normal clinic blood pressure (upper panel) and with prehypertension (upper panel).

| among suckson fleat Study parties | | | ASCVD risk catego | 1 /1 | <u> </u> | | |
|--|--------------------------------------|--------------------|------------------------|---------------------|----------|--|--|
| | <5% | ≥5% to <7.5% | ≥7.5% to <10% | ≥10% | p-trend | | |
| Among participants with normal clinic blood pressure | n=112 | n=36 | n=26 | n=60 | | | |
| | | | Prevalence | | | | |
| Any masked hypertension | 25.9% | 44.4% | 46.2% | 53.3% | < 0.001 | | |
| Masked daytime hypertension | 8.9% | 22.2% | 23.1% | 23.3% | 0.001 | | |
| Masked nighttime hypertension | 23.2% | 33.3% | 38.5% | 50.0% | < 0.001 | | |
| Masked 24-hour hypertension | 9.8% | 22.2% | 23.1% | 30.0% | 0.001 | | |
| | | Unadjust | ed prevalence ratio (| 95% CI) | | | |
| Any masked hypertension | 1 (ref) | 1.72 (1.06 - 2.78) | 1.78 (1.06 - 3.00) | 2.06 (1.39 - 3.05) | < 0.001 | | |
| Masked daytime hypertension | 1 (ref) | 2.49 (1.06 - 5.83) | 2.58 (1.03 - 6.47) | 2.61 (1.24 - 5.52) | 0.007 | | |
| Masked nighttime hypertension | 1 (ref) | 1.44 (0.81 - 2.54) | 1.66 (0.92 - 2.99) | 2.15 (1.41 - 3.28) | < 0.001 | | |
| Masked 24-hour hypertension | 1 (ref) | 2.26 (0.99 - 5.19) | 2.35 (0.96 - 5.77) | 3.05 (1.55 - 6.04) | < 0.001 | | |
| | | Adjusted | d prevalence ratio (95 | 5% CI)* | | | |
| Any masked hypertension | 1 (ref) | 1.73 (1.01 - 2.97) | 1.88 (1.00 - 3.54) | 2.22 (1.24 - 3.99) | 0.015 | | |
| Masked daytime hypertension | 1 (ref) | 2.73 (0.97 - 7.69) | 2.72 (0.82 - 8.98) | 3.35 (1.02 - 11.01) | 0.109 | | |
| Masked nighttime hypertension | 1 (ref) | 1.45 (0.78 - 2.70) | 1.77 (0.87 - 3.58) | 2.38 (1.27 - 4.45) | 0.006 | | |
| Masked 24-hour hypertension | 1 (ref) | 1.97 (0.80 - 4.86) | 2.04 (0.68 - 6.09) | 2.75 (1.01 - 7.45) | 0.078 | | |
| Among participants with prehypertension | n=100 | n=57 | n=48 | n=205 | | | |
| | | | Prevalence | | | | |
| Any masked hypertension | 52.0% | 54.4% | 64.6% | 70.7% | 0.001 | | |
| Masked daytime hypertension | 34.0% | 29.8% | 35.4% | 47.3% | 0.009 | | |
| Masked nighttime hypertension | 49.0% | 47.4% | 60.4% | 65.4% | 0.002 | | |
| Masked 24-hour hypertension | 35.0% | 31.6% | 41.7% | 52.7% | 0.001 | | |
| | Unadjusted prevalence ratio (95% CI) | | | | | | |
| Any masked hypertension | 1 (ref) | 1.05 (0.77 - 1.42) | 1.24 (0.94 - 1.65) | 1.36 (1.10 - 1.67) | 0.001 | | |
| Masked daytime hypertension | 1 (ref) | 0.88 (0.54 - 1.42) | 1.04 (0.65 - 1.67) | 1.39 (1.02 - 1.90) | 0.012 | | |
| Masked nighttime hypertension | 1 (ref) | 0.97 (0.69 - 1.36) | 1.23 (0.91 - 1.67) | 1.33 (1.07 - 1.67) | 0.003 | | |

| Masked 24-hour hypertension | 1 (ref) | 0.90 (0.57 - 1.44) | 1.19 (0.78 - 1.83) | 1.51 (1.12 - 2.03) | 0.001 | | | |
|-------------------------------|---------|-------------------------------------|--------------------|--------------------|-------|--|--|--|
| | | Adjusted prevalence ratio (95% CI)* | | | | | | |
| Any masked hypertension | 1 (ref) | 1.06 (0.77 - 1.44) | 1.29 (0.94 - 1.75) | 1.42 (1.07 - 1.89) | 0.007 | | | |
| Masked daytime hypertension | 1 (ref) | 0.98 (0.60 - 1.61) | 1.20 (0.73 - 1.97) | 1.72 (1.11 - 2.66) | 0.006 | | | |
| Masked nighttime hypertension | 1 (ref) | 0.89 (0.63 - 1.27) | 1.11 (0.79 - 1.57) | 1.13 (0.81 - 1.58) | 0.282 | | | |
| Masked 24-hour hypertension | 1 (ref) | 0.94 (0.58 - 1.51) | 1.22 (0.78 - 1.90) | 1.55 (1.02 - 2.35) | 0.013 | | | |

ASCVD: Atherosclerotic cardiovascular disease

CI: Confidence interval

Normal clinic blood pressure is defined as mean clinic systolic blood pressure <120 mm Hg and mean clinic diastolic blood pressure <80 mm Hg. Prehypertension is defined as mean clinic systolic blood pressure 120 to 139 mm Hg or mean clinic diastolic blood pressure 80 to 89 mm Hg.

^{*}Adjusted for age, sex, body mass index, less than high school education, and estimated glomerular filtration rate <60 ml/min/m²

Supplemental Table 7. C-statistic for masked hypertension using 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk compared with clinic systolic blood pressure (SBP) and diastolic blood pressure (DBP), clinic SBP alone, and clinic DBP alone among Jackson

Heart Study participants not taking and taking antihypertensive medication in adjusted models.

| | | Adjusted o | e-statistic* | Difference in c-statistic (95% CI) | | | |
|------------------|-------------------|--------------------|-----------------|------------------------------------|----------------------|-------------------|--------------------|
| | 10-year predicted | Clinia CDD and | | | Clinic SBP and DBP | Clinic SBP versus | Clinic DBP |
| | ASCVD Risk | Clinic SBP and DBP | Clinic SBP | Clinic DBP | versus ASCVD risk | ASCVD risk | versus ASCVD |
| | Score | DDL | | | score† | score‡ | risk score§ |
| | | | Participants | not taking antihyp | ertensive medication | | |
| Any masked | 0.655 (0.593 to | 0.740 (0.684 to | 0.740 (0.684 to | 0.656 (0.594 to | 0.085 | 0.085 | 0.001 |
| hypertension | 0.718) | 0.797) | 0.797) | 0.718) | (0.037 to 0.150) | (0.038 to 0.154) | (-0.054 to 0.056) |
| Masked daytime | 0.682 (0.636 to | 0.721 (0.680 to | 0.721 (0.679 to | 0.651 (0.606 to | 0.039 | 0.039 | -0.031 |
| hypertension | 0.728) | 0.763) | 0.762) | 0.697) | (0.000 to 0.030) | (-0.006 to 0.031) | (-0.107 to -0.013) |
| Masked nighttime | 0.664 (0.621 to | 0.689 (0.648 to | 0.689 (0.648 to | 0.646 (0.603 to | 0.025 | 0.025 | -0.018 |
| hypertension | 0.706) | 0.730) | 0.730) | 0.689) | (-0.010 to 0.034) | (-0.010 to 0.037) | (-0.095 to 0.009) |
| Masked 24-hour | 0.696 (0.652 to | 0.732 (0.691 to | 0.730 (0.690 to | 0.662 (0.618 to | 0.036 | 0.035 | -0.033 |
| hypertension | 0.739) | 0.772) | 0.771) | 0.707) | (-0.010 to 0.044) | (-0.025 to 0.051) | (-0.112 to 0.001) |
| | | | Participan | ts taking antihyper | tensive medication | | |
| Any masked | 0.697 (0.641 to | 0.689 (0.632 to | 0.690 (0.632 to | 0.664 (0.606 to | -0.008 | -0.008 | -0.033 |
| hypertension | 0.754) | 0.747) | 0.747) | 0.723) | (-0.056 to 0.026) | (-0.050 to 0.031) | (-0.082 to 0.006) |
| Masked daytime | 0.682 (0.636 to | 0.721 (0.680 to | 0.721 (0.679 to | 0.651 (0.606 to | 0.039 | 0.039 | -0.031 |
| hypertension | 0.728) | 0.763) | 0.762) | 0.697) | (0.041 to 0.095) | (0.043 to 0.094) | (-0.061 to 0.022) |
| Masked nighttime | 0.664 (0.621 to | 0.689 (0.648 to | 0.689 (0.648 to | 0.646 (0.603 to | 0.025 | 0.025 | -0.018 |
| hypertension | 0.706) | 0.730) | 0.730) | 0.689) | (0.013 to 0.064) | (0.016 to 0.053) | (-0.050 to 0.028) |
| Masked 24-hour | 0.696 (0.652 to | 0.732 (0.691 to | 0.730 (0.690 to | 0.662 (0.618 to | 0.036 | 0.035 | -0.033 |
| hypertension | 0.739) | 0.772) | 0.771) | 0.707) | (0.031 to 0.076) | (0.034 to 0.071) | (-0.068 to 0.005) |

Statistically significant differences versus ASCVD risk score are shown in bold.

ASCVD: Atherosclerotic cardiovascular disease

CI: Confidence interval

SBP: Systolic blood pressure DBP: Diastolic blood pressure

^{*}Adjusted for age, sex, body mass index, less than high school education, and estimated glomerular filtration rate <60 ml/min/m²

[†]Comparing clinic SBP and DBP to 10-year predicted ASCVD Risk Score

[‡]Comparing clinic SBP to 10-year predicted ASCVD Risk Score

[§]Comparing clinic DBP to 10-year predicted ASCVD Risk Score

SUPPLEMENTAL FIGURES

Supplemental Figure 1. Prevalence of 10-year predicted atherosclerotic cardiovascular disease risk categories among participants with and without masked hypertension stratified by those not taking antihypertensive medication (upper panel) and those taking antihypertensive medication (lower panel). The prevalence data, depicted here, are presented in Supplemental Table 5.



